IRVINE, Calif., May 21 /PRNewswire-FirstCall/ -- Endocare, Inc. , an innovative medical device company focused on the development of minimally invasive technologies used by urologists and interventional radiologists for tissue and tumor ablation, announced today that cryoablation, a minimally invasive method of freezing cancerous tumors to destroy them, was the focus of 17 clinical studies presented at the six-day annual meeting of the American Urological Association (AUA) in Orlando, which is the largest urology meeting of the year.
Also, a total of six post-graduate educational courses and workshops related to cryoablation were sponsored by the AUA and, for the first time, the AUA adopted a specific set of prostate cancer clinical guidelines for cryoablation. A panel, led by Richard J. Babaian M.D. professor and senior medical director at M.D. Anderson Physician Network, announced a set of best practice statements for primary cryoablation, salvage cryoablation and focal cryoablation.
“The positive outcomes cryoablation has had for thousands of patients were evident in a variety of clinical studies presented by leading physicians and researchers throughout this year’s AUA annual meeting,” said Endocare Chairman, CEO and President Craig T. Davenport. “The breadth of attention that the AUA now pays to cryoablation, including educational courses, workshops and the adoption of AUA-sponsored clinical guidelines, underscores the acceptance of cryoablation as a safe and effective, minimally invasive treatment for prostate cancer and kidney cancer.”
About Endocare
Endocare, Inc. -- http://www.endocare.com -- is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).
Statements contained in this release that are not historical facts are forward-looking statements that involve risks and uncertainties. Among the important factors which could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, those discussed in “Risk Factors” in the Company’s Forms 10-K, Forms 10-Q, and other filings with the Securities and Exchange Commission. Such risk factors include, but are not limited to, uncertainty regarding the effects of the studies described in this press release and any future follow up data. The actual results that the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. The Company undertakes no obligation to revise, or update publicly, any forward-looking statements for any reason.
CONTACT: Investors, Matt Clawson, matt@allencaron.com, or Media, Len Hall,
len@allencaron.com, both of Allen & Caron, Inc., +1-949-474-4300, for
Endocare, Inc.; or Craig T. Davenport, CEO, or Michael R. Rodriguez, CFO,
both of Endocare, Inc., +1-949-450-5400
Web site: http://www.endocare.com/
